Strikingly, our data suggest PRT543 potently inhibits olaparib-resistant ovarian cancer cell line models with endogenous BRCA1 mutation that have been engineered to re-express BRCA1, as well as long-term drug-induced acquired resistance to olaparib. This evidence concerns the gene BRCA1 and ovarian carcinoma.